[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"menstrual-bleeding-heavy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:menstrual-bleeding-heavy":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,58,87,117],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":41,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100628155","effectiveness-of-an-mhealth-innovation-on-the-impact-of-menstrual-complaints-in-adolescents-100628155",false,"NCT07457957","Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents","The Effectiveness of an mHealth Innovation on the Impact of Menstrual Complaints in Adolescents - A Randomised Controlled Trial","MGA","Inclusion Criteria:\n\n* Dutch, English, Turkish or Moroccan-Arabic speaking\n* Post menarche\n* Access to a smartphone or tablet with iOS or Android operating system\n\nExclusion Criteria:\n\n* Amenorrhea\n* Pregnancy\n* No menstrual bleeding or withdrawel bleeding in the 3 months prior to inclusion.\n* Previously or currently under treatment by a health care provider for menstrual complaints",true,"FEMALE","12 Years","21 Years",{"count":22,"type":23},874,"ESTIMATED","INTERVENTIONAL",[26],"NA","The aim of this study is to improve menstrual health-related quality of life in adolescents by using a mobile menstrual health tracker. We will perform a randomized controlled trial to evaluate the (cost)-effectiveness of this mHealth intervention.",[29,30,31,32,33,34,35,36,37,38,39,40],"Dysmenorrhea","Heavy Menstrual Bleeding","Menstrual Cramps","Menstrual Bleeding, Heavy","Menstrual Discomfort","Menstrual Cycle Abnormal","Menstrual Disorder","Menstrual Health","Mobile Application","mHealth","Menstrual Health Intervention","Adolescent",[42,38,43,40,44],"randomized clinical trial","Menstrual health","Menstrual Tracker App","NOT_YET_RECRUITING","2026-03-04",{"date":48,"type":49},"2026-03-09","ACTUAL",{"date":51,"type":23},"2026-02-16",{"date":53,"type":23},"2029-05-31",{"name":55,"class":56},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":18,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":57},"100505091","novasure-study-endometrial-ablation-in-women-with-heavy-menstrual-bleeding-100505091","NCT05856838","NovaSure Study: Endometrial Ablation in Women With Heavy Menstrual Bleeding","Radiofrequency Ablation in Women With Heavy Menstrual Bleeding, Procedure in an Outpatient Setting","RAMBOS","Inclusion Criteria:\n\n* ≥ 35 years - ≤ 50 years\n* Heavy menstrual bleeding (PBAC ≥ 150)\n* Unsuccessful drug treatment, contraindication to drug treatment or rejection of drug treatment by the patient\n* The absence of intra-uterine abnormalities on diagnostic hysteroscopy\n* Endometrial biopsy (pipelle) is normal\n* Finished childbearing\n\nExclusion Criteria:\n\n* Pregnancy\n* Endometritis\n* Adenomyosis\n* Contra-indication for local anaesthetics\n* Presence of severe systemic disease (≥ASA 3)\n* Previously performed endometrial ablation\n* Poor understanding of Dutch language\n* History of pelvic malignancy\n* Presence of an intra uterine device (IUD)\n* Cavity pathology (myoma, septum)\n* Cavity length \\\u003C 4 cm\n* Each uterine incision other than conventional caesarean incision","35 Years","50 Years",{"count":69,"type":23},30,[26],"Heavy menstrual bleeding (HMB) affects 30% of women worldwide. It negatively influences physical activity, work productivity, sexual life and overall quality of life.\n\nIn 2018, the FIGO (International Federation of Gynaecology and Obstetrics) revised its definition of AUB (FIGO-AUB system 1) and the classification of the underlying causes (FIGO-AUB system 2). It includes HMB, which is a subjective parameter and therefore patient determined. The FIGO-AUB system 2 describes the underlying causes of AUB through the acronym PALM-COEIN: Polyps, Adenomyosis, Leiomyomatosis, Malignancy, Coagulopathy, Endometrial, Iatrogenic and not otherwise specified.\n\nThe National Institute for Health and Care Excellence (NICE) guideline on HMB recommends the levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg as the treatment of first choice in women with no identified pathology, fibroids less than 3cm in diameter, which are not causing distortion of the uterine cavity, or adenomyosis. If a woman declines a LNG-IUS, non-hormonal (fibrinolytics or non-steroidal anti-inflammatory drugs (NSAIDs)) and other hormonal pharmacological treatments can be considered. If treatment is unsuccessful, the woman declines pharmacological treatment, or symptoms are severe, an endometrial ablation (EA) or hysterectomy can be an alternative option. The latter is a definitive solution, but it is an invasive option, with a risk of serious complications.\n\nAn EA is a procedure that destroys the endometrium. It aims to reduce the menstrual flow, sometimes causing amenorrhea. Initially, it was performed through hysteroscopy. Later on, second-generation devices became available. NovaSure is an example of a second-generation EA device, using a bipolar radiofrequency impedance-controlled system that evaporates endometrial tissue. The EA procedure is a minimally invasive alternative to hysterectomy. It is known to result in amenorrhea in 50% of women, with satisfaction rates between 80-96% and reported reintervention rates around 10%. Moreover, it is feasible to perform the procedure using only local anaesthesia.\n\nThe investigators aim to assess the patient acceptability and feasibility of NovaSure EA in an outpatient setting with a short observation (≤4 hours)\n\nThis observational prospective cohort study will be performed in the Ghent University Hospital (Ghent), Leuven Catholic University Hospital (Leuven) and Turnhout General Hospital (Turnhout).\n\nThe surgeon performing the procedure will be the same per institution. The duration of the study is estimated at 4 months.",[32],[74,75,76],"Menorrhagia\u002Fsurgery","Endometrial Ablation Techniques","Endometrium\u002Fsurgery","RECRUITING","2025-12-18",{"date":80,"type":49},"2025-12-26",{"date":82,"type":49},"2023-11-24",{"date":84,"type":23},"2026-12-31",{"name":86,"class":56},"University Hospital, Ghent",{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":4,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":18,"minAge":94,"maxAge":95,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":99,"conditions":100,"keywords":104,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":57},"100599455","moderate-aerobic-exercise-for-managing-menstrual-cycle-symptoms-100599455","NCT07084714","Moderate Aerobic Exercise for Managing Menstrual Cycle Symptoms","Impact of Moderate Aerobic Exercise on Menstrual Cycle Symptoms in Sedentary Women","Inclusion Criteria:\n\n* premenopausal (defined as having regular menstrual periods every 21-35 days)\n* either not using hormonal or non-hormonal contraceptives (i.e., intrauterine device) for the past 6 months OR using combined oral contraceptives (i.e., those that contain progesterone and estrogen) for at least the past 6 months\n* not currently pregnant or trying to become pregnant\n* sedentary lifestyle (score of \"low activity\u002Finactive\" assessed using the IPAQ)\n* have self reported menstrual cycle symptoms (symptoms reported on the PSST or MSi)\n* do not have a medical diagnosis or signs\u002Fsymptoms of diabetes, cardiovascular, or renal disease and are able to participate in moderate intensity physical activity without physician clearance\n\nExclusion Criteria:\n\n* becoming physically active defined as scoring higher than \"low activity\u002Finactive\" on the IPAQ during the first month of the study\n* non compliance with instructions provided for the moderate aerobic exercise intervention (i.e., not adhering to predetermined intensity heart rate targets) or miss more than 25% of exercise sessions in either intervention month\n* becoming pregnant during enrollment\n* being diagnosed with a cardiovascular, metabolic, or renal disease that would require physical clearance to participate in moderate intensity aerobic physical activity\n* begin using hormonal or non-hormonal (i.e., intrauterine devices) contraceptives if assigned to the arm not using hormonal contraceptives\n* either begin a different type of contraceptive or discontinue combined hormonal contraceptive use if assigned to the hormonal contraceptive arm","18 Years","40 Years",{"count":97,"type":23},35,[26],"The goal of this clinical trial is to evaluate the impact of moderate aerobic exercise on menstrual symptom management in sedentary women both using and not using hormonal contraceptives. The main questions it aims to answer are:\n\nIs there a reduction in physical and\u002For psychological menstrual cycle related symptom burden with participation in moderate aerobic exercise for sedentary women using and not using hormonal contraceptives?\n\nIs there a difference in physical and\u002For psychological menstrual cycle related symptom burden between hormonal contraceptive and non-hormonal contraceptive users?\n\nIs a moderate aerobic exercise intervention more effective in reducing physical and\u002For psychological menstrual related symptom burden for sedentary women using or not using hormonal contraceptives?\n\nParticipants will:\n\n* Have their body composition assessed using dual energy X-ray absorptiometry pre and post exercise intervention.\n* Complete a Menstrual Symptom Index (MSi) to report daily menstrual cycle related symptom burden in addition to the Premenstrual Symptom Screening Tool (PSST) and Heavy Menstrual Bleeding (HMB) questionnaire monthly.\n* Utilize an at-home monitor to test urinary luteinizing hormone, estrone-3-glucuronide, and pregnanediol glucuronide approximately 10 times per month and report menstrual cycle length.\n* Record physical activity habits by continuously wearing a wrist-based accelerometer and chest-strap heart rate monitor during planned aerobic exercise sessions and complete the International Physical Activity Questionnaire (IPAQ) monthly.\n* Maintain their usual sedentary activity habits for one menstrual cycle followed by completion of an exercise intervention designed to progress individuals to meet minimum recommended aerobic physical activity guidelines of 150 minutes per week set by the American College of Sports Medicine for two menstrual cycles.",[101,102,103,32],"Premenstrual Syndrome","Menstrual Cycle","Menstrual Distress (Dysmenorrhea)",[105,106,107],"menstrual cycle","premenstrual syndrome","dysmenorrhea","2025-07-17",{"date":110,"type":49},"2025-07-24",{"date":112,"type":23},"2025-07",{"date":114,"type":23},"2026-08",{"name":116,"class":56},"University of Colorado, Colorado Springs",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":17,"sex":18,"minAge":94,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":24,"phases":127,"briefSummary":130,"conditions":131,"keywords":4,"overallStatus":77,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":57},"100505547","phase-1-pai-1-tpa-tfpi-and-heecs-in-uterine-hemostasis-100505547","NCT05862805","PAI-1, tPA, TFPI and HEECs in Uterine Hemostasis","The Role of Plasminogen Activator Inhibitor-1 (PAI-1), Tissue Plasminogen Activator (tPA), Tissue Factor Pathway Inhibitor (TFPI), and Endometrial Endothelial Cells in Uterine Hemostasis in Humans","Inclusion Criteria:\n\n* Regularly menstruating participants between 18-45 years of age\n\nExclusion Criteria:\n\n* Pregnancy within 3 months of enrollment\n* Lactating at the time of enrollment\n* Hormonal contraceptive use or use of the copper intrauterine device (IUD)\n* Antifibrinolytic use\n* Inherited or acquired bleeding disorder or anticoagulant use\n* Known structural cause of HMB\n* Inability to complete PBACs\n* Unwilling to refrain from sexual intercourse for the two weeks prior to endometrial biopsy","45 Years",{"count":126,"type":23},70,[128,129],"PHASE1","PHASE2","The purpose of the study is to learn more about the role of blood clotting factor proteins and cells in menstrual (period) bleeding. The investigators are hoping to identify differences in these proteins and cells in the menstrual blood of individuals with heavy periods compared to menstruating individuals who do not have heavy periods.",[32],"2024-08-16",{"date":134,"type":49},"2024-08-19",{"date":136,"type":49},"2023-07-12",{"date":138,"type":23},"2026-07",{"name":140,"class":56},"Oregon Health and Science University"]